Gene Delivery

Drug discovery firm receives patent for functional biology platform

Published in Gene Therapy Weekly, July 10th, 2003

Tranzyme, Inc., a drug discovery company focused on diseases of the neurosensory system, announced the issuance of a new patent related to the company's gene delivery technology, TranzVector. This U.S. patent provides key intellectual property for the packaging of lentiviral and retroviral gene transfer vectors.

The patent specifically covers the use of the Gag polyprotein to mediate the packaging of functional reverse transcriptase (RT) and integrase (IN) independently of native Gag-Pol expression. RT and IN are normally expressed as components of the Gag-Pol precursor protein in replication-competent viruses. Since this invention enables functional RT and IN to be...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2003-07-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry